Page last updated: 2024-10-15

4-((3-(1,6-dihyro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid

Description

4-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid: a neuroprotective agent that has been shown to improve memory; induces NGF-dependent nociceptive nerve sprouting [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135409548
CHEMBL ID2104345
CHEBI ID135395
SCHEMBL ID358491
MeSH IDM0228642

Synonyms (26)

Synonym
138117-50-7
nby3iu407m ,
leteprinim [inn]
unii-nby3iu407m
benzoic acid, 4-((3-(1,6-dihydro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)-
4-((3-(1,6-dihyro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid
ait 082
leteprinim
n-(4-carboxyphenyl)-3-(6-oxohydropurin-9-yl)propanamide
4-((3-(1,6-dihydro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid
p-(3-(1,6-dihydro-6-oxo-9h-purin-9-yl)propionamido)benzoic acid
CHEBI:135395
4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoic acid
CHEMBL2104345
leteprinim [who-dd]
leteprinim [mi]
SCHEMBL358491
4-[[3-(1,6-dihydro-6-oxo-9h-purin-9-yl)-1-oxopropyl]amino]benzoic acid
JMPOIZCOJJMTHI-UHFFFAOYSA-N
4-(3-(6-oxo-3h-purin-9(6h)-yl)propanamido)benzoic acid
DTXSID00160496
Q6533215
SB17518
4-[3-(6-oxo-1h-purin-9-yl)propanoylamino]benzoic acid
4-(3-(6-oxo-3h-purin-9(6h)-yl)propanamido)benzoicacid
AKOS040752496

Dosage Studied

ExcerptReference
" Performance on the Number Comparison, Symbol Digit, and Trails A tests improved with AIT-082 dosing compared to baseline (placebo)."( A phase I study of AIT-082 in healthy elderly volunteers.
Campbell, K; Capparelli, E; Farlow, M; Ferris, SH; Grundman, M; Hake, AM; Kim, HT; Mobs, R; Peavy, G; Salmon, DP; Schafer, K; Schoos, B; Schultz, AN; Thal, LJ; Thomas, RG, 2002
)
" In a second experiment we studied the effect of AIT-082 (30 mg/kg) at the onset of disease and during survival of transgenic G93A SOD1 mice, beginning dosing at different ages (20, 30, 40, 60, 80 days)."( A study of the purine derivative AIT-082 in G93A SOD1 transgenic mice.
Jiang, F; Kwiecien, J; Li, WP; Turnbull, J,
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amidobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (19.05)18.2507
2000's14 (66.67)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (84.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]